Mapp Biopharmaceutical
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
6160 Lusk Blvd Ste C200, San Diego, Cali...Phone Number
(800) 372-2176Website
www.mappbio.comRevenue
$14.9 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Mapp Biopharmaceutical
Mapp Biopharmaceutical, Inc. specializes in developing novel pharmaceuticals aimed at preventing and treating infectious diseases, with a strong emphasis on global health and biodefense. The company is actively engaged in human trials for innovative therapies, including monoclonal antibodies for diseases such as Nipah and Marburg virus. Their intended clients include healthcare providers and organizations focused on addressing unmet needs in infectious disease management. Collaborations with entities like BARDA highlight their commitment to advancing therapeutic solutions for critical health threats.Explore more
Mapp Biopharmaceutical Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Mapp Biopharmaceutical your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Mapp Biopharmaceutical recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Mapp Biopharmaceutical has new funding data
Mapp Biopharmaceutical, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Mapp Biopharmaceutical launches new products
Congratulate Masked Content for being promoted to Masked Content at Mapp Biopharmaceutical
Check out if Mapp Biopharmaceutical is spiking on competitors!
Click to see if Mapp Biopharmaceutical had a recent Job posting/layoffs
Check if Mapp Biopharmaceutical has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Mapp Biopharmaceutical as Masked Content
Find 3 more new buyers
Compare Similar Companies to Mapp Biopharmaceutical
Compare insights from companies similar to Mapp Biopharmaceutical, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Mapp Biopharmaceutical is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Mapp Biopharmaceutical is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Mapp Biopharmaceutical.
Mapp Biopharmaceutical Tech Stack
A closer look at the technologies used by Mapp Biopharmaceutical
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Open Position
Mapp Biopharmaceutical News & Media
KBI Biopharma Announces Subcontract with Mapp Biopharmaceutical on Sudan ebolavirus Treatment
DURHAM, N.C.--(BUSINESS WIRE)--KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced it entered into a subcontract with Mapp Biopharmaceutical, Inc. (Mapp) for the continued development and manufacturing of MBP134, an experimental combination monoclonal antibody treatment for Sudan ebolavirus (SUDV)*. With the recent outbreak in Uganda, Mapp was contracted by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic PreparedneMappBio Announces Contract with BARDA for MBP091 as a pan-Marburg Medical Countermeasure
SAN DIEGO, June 11, 2019 /PRNewswire/ -- Mapp Biopharmaceutical, Inc. (MappBio), announced today that it has been awarded an advanced research and development contract for $16.5 million with options for an additional $30.0 million by the Biomedical Advanced Research and Development...Developing vaccines and therapies for the highly pathogenic Nipah and Hendra viruses
Bethesda, Maryland, March 25, 2019 (GLOBE NEWSWIRE) -- Bethesda, MD, March 20, 2019 – The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF), along with Uniformed Services University of the Health Sciences (USU), Profectus Biosciences, Inc., the Vanderbilt University Medical Center, Mapp Biopharmaceutical, Inc., and the University of Texas Medical Branch (UTMB) have been awarded up to $24.5 million to advance treatments for two lethal henipaviruses. The award was maMappBio Announces Contract with BARDA for Sudan Virus Medical Countermeasure
SAN DIEGO, Sept. 28, 2018 /PRNewswire/ -- Mapp Biopharmaceutical, Inc. (MappBio), announced today that it has been awarded a contract (HHSO100201800024C) of $14.8 million with options for an additional $32.0 million by the Biomedical Advanced Research and Development Authority (BARDA),...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Mapp Biopharmaceutical
Sign Up For FreeTo access detailed company insights
Mapp Biopharmaceutical, Inc. specializes in developing novel pharmaceuticals aimed at preventing and treating infectious diseases, with a strong emphasis on global health and biodefense. The company is actively engaged in human trials for innovative therapies, including monoclonal antibodies for diseases such as Nipah and Marburg virus. Their inten... Read More
